Behcet's Disease - Epidemiology Forecast - 2032

DelveInsight's 'Behcet's Syndrome - Epidemiology Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology of Behcet's syndrome in the United States, Japan, EU4 (Germany, Spain, Italy, France) and the United Kingdom.

Behcet's Syndrome: Disease Understanding

Behcet's syndrome Overview

According to American Behcet's Disease Association (ABDA) and National Organization for Rare Disorders (NORD), Behcet's syndrome/Behcet's disease (BD) is a rare multisystem inflammatory disorder characterized by ulcers affecting the mouth and genitals, various skin lesions, and abnormalities affecting the eyes. In 1937, Turkish dermatologist Hulusi Behcet called attention to the association of oral and genital ulcerations with hypopyon-uveitis. Since then, Behcet's syndrome has become associated with several additional clinical manifestations, each attributed to an underlying vasculitis affecting vessels of all sizes.

The disease is recognized worldwide, but there are significant differences in the epidemiological, genetic, and clinical characteristics of the disorder between ethnic groups and in different geographic locations. As there are no specific manifestations nor specific diagnostic tests, the term Behcet's syndrome is preferred by some authors, especially for patients from low-prevalence areas whose disease manifestations are generally less severe and possibly due to other underlying conditions. The disease is associated with significant morbidity and mortality. The morbidity of Behcet's syndrome comes primarily from ocular involvement, and mortality relates primarily to large vessel involvement and central nervous system disease.

Treatment is dependent on the site and severity of manifestations; OTEZLA (apremilast), an oral selective phosphodiesterase 4 (PDE4) inhibitor, is the first and only approved treatment by the US Food and Drug Administration (FDA) for oral ulcers associated with Behcet's syndrome. OTEZLA was approved in 2019 as a 30 mg twice-daily therapy for adult patients in the US. In Japan, infliximab (2007) and HUMIRA (adalimumab; 2013) were approved for managing systemic and intestinal Behcet's syndrome, and TNF inhibitors are considered the drug of choice in refractory cases of the disease. Pharmacological management involves using various off-label therapies like corticosteroids and other immunosuppressants. Surgery is usually indicated for treating systemic arterial aneurysms because of the risk of rupture, but isolated arterial occlusions may be asymptomatic and not require surgery.

Epidemiology

The Behcet's syndrome epidemiology division provides insights into the historical and current patient pool and the forecast trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Behcet's syndrome epidemiology segmented as the diagnosed prevalent cases of Behcet's syndrome, cases of Behcet's syndrome based on the age of onset, and clinical manifestations associated with Behcet's syndrome. The report includes the prevalent scenario of Behcet's syndrome in the 7MM covering the United States, Japan, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom from 2019 to 2032.

Country-wise, Behcet's syndrome Epidemiology

The epidemiology segment also provides Behcet's syndrome epidemiology data and findings across the United States, Japan, EU4 (Germany, France, Italy, Spain) and the United Kingdom.

The total diagnosed prevalent patient population of Behcet's syndrome in the 7MM countries was approximately 69,000 cases in 2021.

As per the estimates, Japan had the highest prevalent patient population of Behcet's syndrome in 2021. Among the EU4 countries, Italy had the highest diagnosed patient population of Behcet's syndrome, with more than 6,000 cases, followed by France in 2021. On the other hand, Germany had the lowest diagnosed prevalent patient population of Behcet's syndrome, with ~1,000 cases in 2021.

Scope of the Report:

• Behcet's syndrome report covers a detailed overview explaining its causes, symptoms and classification, pathophysiology, diagnosis, and treatment patterns.
• Behcet's syndrome epidemiology report and model provide an overview of the risk factors and global trends of Behcet's syndrome in the 7MM: EU4 (Germany, Spain, France, and Italy) and the UK, and Japan.
• The report provides insight into the historical and forecasted patient pool of Behcet's syndrome in seven major markets covering the United States, Japan, EU4 (Germany, Spain, France, Italy) and the UK.
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Behcet's syndrome.
• The report describes Behcet's syndrome epidemiology by prevalent cases of Behcet's syndrome in the 7MM.
• The report describes the epidemiology of Behcet's syndrome by diagnosed cases of Behcet's syndrome in the 7MM.
• The report provides the segmentation of Behcet's syndrome epidemiology by the prevalence of Behcet's syndrome based on symptoms in the 7MM.
• The report provides the segmentation of Behcet's syndrome epidemiology by the age-specific cases of Behcet's syndrome patients in the 7MM.
• The report segments Behcet's syndrome epidemiology by gender-specific cases of Behcet's syndrome in the 7MM.

Report Highlights:

• 11-year Forecast of Behcet's syndrome Epidemiology
• The 7MM Coverage
• Diagnosed Prevalent cases of Behcet's syndrome
• Cases of Behcet's syndrome based on the age of onset
• Clinical manifestations associated with Behcet's syndrome

KOL Views

We interview KOLs and obtain SMEs' opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential novel treatments by identifying the overall scenario of the indications.

Key Questions Answered

• What major factors will drive the change in the patient population in an indication of Behcet's syndrome during the forecast period (2019-2032)?
• What key findings about Behcet's syndrome epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients with Behcet's syndrome across the 7MM forecast period (2019-2032)?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR is the patient population expected to grow in the 7MM forecast period (2019-2032)?
• What are Behcet's syndrome's disease risks, burdens, and unmet needs?
• What are the currently available treatments for Behcet's syndrome?

Reasons to buy:

Behcet's syndrome epidemiology report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the global Behcet's syndrome market.
• Quantify patient populations in the global Behcet's syndrome market to improve product design, pricing, and launch plans.
• Understand the magnitude of the Behcet's syndrome population by its diagnosed prevalent cases.
• Understand the magnitude of the Behcet's syndrome population by the age of onset.
• Understand the magnitude of the Behcet's syndrome population by clinical manifestations associated with Behcet's syndrome.
• The Behcet's syndrome epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
• The Behcet's syndrome epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered

• The United States
• EU4 (Germany, France, Italy, Spain) and the United Kingdom
• Japan

Study Period: 2019-2032